Sodium-glucose co-transporter 2 (SGLT2) inhibitors

PheWeb

SGLT2INH

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC A10BJ

3436

Check pre-conditions, main-only, mode, ICD version None

3084

Check minimum number of events

Min. number of events 3

3084

Include endpoints None

3084

SGLT2INH

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Sodium-glucose co-transporter 2 (SGLT2) inhibitors based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	2997	1510	1487
Unadjusted prevalence (%)	0.97	0.87	1.10
Mean age at first event (years)	61.34	60.29	62.40

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.04	2.88 [1.80, 4.60]	1.0e-5	39
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: SGLT2INH – Sodium-glucose co-transporter 2 (SGLT2) inhibitors
GWS hits:

Survival analyses between endpoints

↥

Plot

before Sodium-glucose co-transporter 2 (SGLT2) inhibitors
after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

↥